Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




May
19
Today In Oncology
Providing Culturally Sensitive Palliative Care to Children With Cancer
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer Comparison of Agents
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside